Management of Early Onset Neonatal Septicaemia: Selection of Optimal Antibacterial Regimen for Empiric Treatment

This study has been completed.
Sponsor:
Collaborators:
Estonian Science Foundation
ESPID Small grant award
Information provided by:
University of Tartu
ClinicalTrials.gov Identifier:
NCT00487019
First received: June 14, 2007
Last updated: May 27, 2008
Last verified: May 2008
  Purpose

A prospective two-center antibiotic regimen switch study will be conducted to compare the clinical efficacy of two antibiotic regimens - penicillin/gentamicin versus ampicillin/gentamicin - in the empirical treatment of early onset neonatal sepsis. The influence of either regimen on bowel colonization pattern and on the development of antibiotic resistance of gut microflora will also be assessed. The primary endpoint is the need for a change in antibacterial treatment within 72 hours of therapy, based on pre-defined criteria. Secondary endpoints will be the incidence rate and etiology of early and late onset neonatal sepsis and susceptibility pattern of causative microorganisms; mortality rate within 60 days; duration of hospitalization in NICU; duration of artificial ventilation; colonization pattern and susceptibility of colonizing bacteria (including resistance to empiric antibiotic regimen).


Condition
Early Onset Neonatal Sepsis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Comparative Study of Two Antibiotic Regimen - Penicillin G/Gentamicin Versus Ampicillin/Gentamicin in Empirical Treatment of Early Onset Neonatal Septicaemia

Resource links provided by NLM:


Further study details as provided by University of Tartu:

Enrollment: 281
Study Start Date: August 2006
Study Completion Date: December 2007
Groups/Cohorts
1
Neonates aged <72 h and needing antibacterial therapy for early onset neonatal sepsis
2
Same as group 1

Detailed Description:

A prospective randomized two-centre antibiotic regimen switch study will be conducted in the NICU-s of Tartu University Clinics and of Tallinn Children's Hospital. Initially all patients who need empiric treatment for early onset neonatal sepsis (as defined by Schrag et al. 2002) in Tartu will be treated with penicillin/gentamicin and those in Tallinn with ampicillin/gentamicin. When half of the needed subjects have been recruited, departmental antibiotic regimen will be switched so that ampicillin is used in Tartu and penicillin in Tallinn. Based on the present patient population and hospitalization rate, about 120-150 babies, eligible for the study will be admitted to either units every a year.

In all subjects predefined pre- and intranatal risk factors of infection will be registered. During the NICU stay laboratory and clinical signs of infection, need for respiratory support and vasoactive therapy, enteral and parenteral nutrition will be recorded.

Blood, CSF and urine cultures will be taken according to the routine of the ward but certainly before every change in antibacterial treatment. For colonization studies nasopharyngeal or tracheal and anal swabs will be collected from all neonates admitted during the study period on admission and thereafter biweekly until discharge from the NICU or until the 60th day of treatment. A separate protocol will be followed for microbiological investigations.

The endpoints:

The primary endpoint is the need for a change in antibacterial treatment within 72 hours. In discussions with clinical experts in both wards the following criteria for the change in antibacterial treatment were defined:

  1. proven or suspected meningitis or abdominal infection
  2. isolation from a relevant site of the mother or an infant of a microorganism, resistant to initial empiric treatment regimen in babies with early onset neonatal sepsis or septic shock
  3. deterioration of the clinical status on initial antibiotic regimen and suspected/proven neonatal sepsis
  4. suspected/proven late onset sepsis or nosocomial infection (defined as the development of clinical/ laboratory signs of infection at postnatal age of 72 hours or more)
  5. other situations, where the treating physician considers change in antibiotic regimen necessary - the reasons will be recorded in the case report form Patients, who die before 72 hours or in whom the antibacterial therapy is changed for other than the above-mentioned reasons, will be handled as treatment failures.

Secondary endpoints will be the following:

  • incidence rate and etiology of early and late onset neonatal sepsis, susceptibility pattern of causative microorganisms
  • incidence rate and etiology of nosocomial sepsis, susceptibility pattern of causative microorganisms
  • mortality rate within 60 days
  • duration of hospitalization in NICU stay
  • duration of artificial ventilation
  • colonization pattern and susceptibility of colonizing bacteria (including resistance to empiric antibiotic regimen).
  Eligibility

Ages Eligible for Study:   up to 72 Hours
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Neonates hospitalised within 72h of life and requiring empirical antibacterial treatment for early onset neonatal sepsis.

Criteria

Inclusion Criteria:

  • All neonates, admitted to the study NICU-s at the age of less than 72 hours and needing early empiric antibiotic treatment according to pre-defined criteria as described by Schrag et al. (2002)

Exclusion Criteria:

  • Subjects, who on clinical or other indications (e.g. suspected/proven meningitis or abdominal cavity infection, isolation of resistant bacteria from the mother of a neonate with severe sepsis) need antibiotic treatment other than specified in the study protocol and infants who are likely to be transferred to other units within 24 hours.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00487019

Locations
Estonia
Tallinń's Childrens Hospital, Paediatric Intensive Care Unit
Tallinn, Estonia
Tartu University Clinics, Department of Paediatric Intensive Care
Tartu, Estonia, 50411
Sponsors and Collaborators
University of Tartu
Estonian Science Foundation
ESPID Small grant award
Investigators
Study Chair: Irja Lutsar, MD, PhD University of Tartu
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00487019     History of Changes
Other Study ID Numbers: 038FAR042005
Study First Received: June 14, 2007
Last Updated: May 27, 2008
Health Authority: Estonia: The State Agency of Medicine

Keywords provided by University of Tartu:
ampicillin
penicillin G
gentamicin
neonatal sepsis
empiric therapy

Additional relevant MeSH terms:
Sepsis
Toxemia
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Ampicillin
Anti-Bacterial Agents
Gentamicins
Penicillin G
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 23, 2014